Table 1.
Baseline characteristics by age group.
| <75y (n=426) |
75-85y (n=237) |
>85y (n=90) |
P-value | |
|---|---|---|---|---|
| Median Age | 66.6y | 79.6y | 88.0y | |
| Patient Comorbidities | ||||
| Ischemic Heart Disease | 68 (16%) | 70 (30%) | 37 (41%) | <0.001 |
| Stroke | 22 (5%) | 25 (11%) | 11 (12%) | 0.024 |
| Peripheral Vascular Disease | 9 (2%) | 13 (6%) | 7 (78%) | 0.020 |
| Hypertension | 211 (50%) | 142 (60%) | 66 (73%) | 0.002 |
| Hypercholesterolaemia | 144 (34%) | 104 (44%) | 46 (51%) | 0.036 |
| Diabetes | 57 (13%) | 58 (25%) | 13 (14%) | 0.003 |
| Cognitive Impairment | 12 (3%) | 7 (3%) | 6 (7%) | 0.182 |
| Smoking History | 157 (37%) | 68 (29%) | 36 (40%) | 0.194 |
| Disease Characteristics | ||||
| Gleason Score | ||||
| < 8 | 95 (22%) | 68 (29%) | 16 (18%) | 0.003 |
| ≥ 8 | 231 (54%) | 86 (36%) | 21 (23%) | |
| Unknown | 100 (23%) | 83 (35%) | 53 (59%) | |
| De Novo Metastatic Disease | 112 (26%) | 42 (18%) | 18 (20%) | 0.033 |
| Visceral Metastases | 36 (9%) | 21 (9%) | 7 (8%) | 0.951 |
| Median PSA at mCRPC diagnosis | 54.25 | 64.44 | 81.18 | <0.001 |
| PSA Doubling Time at mCRPC diagnosis | ||||
| ≤3months | 224 (53%) | 113 (48%) | 30 (33%) | 0.014 |
| >3months | 114 (27%) | 76 (32%) | 33 (37%) | |
| Unknown | 88 (21%) | 48 (20%) | 27 (30%) | |
| Prior Curative-Intent Treatment for Localised Disease | 247/314 (79%) | 118/195 (61%) | 31/72 (43%) | <0.001 |
| Prior Upfront Systemic therapy for mHSPC | ||||
| Docetaxel | 87 (20%) | 16 (7%) | 0 | |
| Abiraterone | 1 (<1%) | 2 (1%) | 0 | |
| Enzalutamide | 4 (1%) | 3 (1%) | 0 | |
p values that are statistically significant (<0.05) are displayed in bold.